Journal of medicinal chemistryMar 15, 2012

A new method to find and develop easy-to-use telomerase blockers

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Feb 24, 2026

Abstract

BIBR-1532 and MST-312 inhibit only human telomerase, while β-R, THyF, TMPyP4, and EGCG inhibit both human and Tetrahymena telomerases.

Human telomerase's complex dimeric structure has hindered the development of small-molecule inhibitors.
Monomeric Tetrahymena telomerase was explored as an alternative platform for inhibitor development.
Some small-molecule compounds demonstrated the ability to inhibit both human and Tetrahymena telomerases.
Using Tetrahymena telomerase may provide clearer insights, potentially aiding the discovery of effective inhibitors.

Simplified

Despite intense academic and industrial efforts and innumerable in vitro and cell studies, no small-molecule telomerase inhibitors have emerged as drugs. Insufficient understanding of enzyme structure and mechanisms of interdiction coupled with the substantial complexities presented by its dimeric composition have stalled all progress toward small-molecule therapeutics. Here we challenge the assumption that human telomerase provides the best platform for inhibitor development by probing a monomeric Tetrahymena telomerase with six tool compounds. We find BIBR-1532 (2) and MST-312 (5) inhibit only human telomerase, whereas β-R (1), THyF (3), TMPyP4 (6), and EGCG (4) inhibit both enzymes. Our study demonstrates that some small-molecule scaffolds can be easily surveyed with in vitro studies using Tetrahymena telomerase, a finding that could lead to more tractable inhibitors with a greater potential for development given the more precise insights that can be gleaned from this more easily expressed and assayed monomeric enzyme.

Full Text

Full text is available at the source.

View Full Text ↗

A new method to find and develop easy-to-use telomerase blockers

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief